An investigative report by a group of Swiss newspapers has revealed the extent to which pharmaceutical companies are funding hospitals, doctors, and medical centres in the country.
CHF458 million ($456.5 million): this was the amount paid by the 60 pharma companies based in Switzerland to various arms of the medical profession between 2015 and 2017, according to a report by the Beobachter, Handelszeitung, Blick, and Le Temps newspapers.
Of the 2017 amount of CHF162.5 million (over CHF20 million more than in 2015), over half was paid to medical associations, university hospitals, and other organisations, the journalists reported based on data from the Scienceindustries pharma group.
Another CHF60 million of this was earmarked for research projects.
For its part, the Le Temps newspaper focused heavilyExternal link on the CHF7 million that found its way to medical groups responsible for further education of medical professionals, a figure that the French-speaking newspaper called “troubling”.
“Is it normal that doctors receive training funded by the industry for whom they will in future prescribe products?” it asks.
Transparency
In terms of the overall 2017 figure, pharma giant Novartis was the most generous, allocating just under CHF20 million to various areas. Roche donated CHF13.9 million, and Bayer CHF12 million.
The industry, and its links to the medical profession, are nevertheless on a drive to increase transparency; some 73% of doctors are willing to publicly publish their names as recipients of such funding, according to BeobachterExternal link.
This marks a much more open situation than that in neighbouring Germany or Austria, for example, where publicly disclosed names only make up 30% of cases.
Novartis, for one, also refuses to donate to any source unwilling to claim publicly.
What do you think Switzerland’s Alain Berset can bring to the Council of Europe?
The former interior minister is to become the first Swiss Secretary General of the Council of Europe – which issues should his five-year term focus on?
How is your country dealing with the return of stolen artifacts?
Western nations like Switzerland often have to deal with the process of recovering or returning looted artifacts which have been illegally imported. What’s the situation like in your country?
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
High pharma margins squeeze health systems
This content was published on
Curing cancer for the masses could be challenging if healthcare systems are crippled by rapidly rising cancer drug prices.
Too few pharma companies prioritise access to medicines
This content was published on
Novartis and Roche both get a boost in the 2018 ranking of progress in expanding access to medicines by the biggest pharmaceutical companies.
This content was published on
The company formed when Ciba Geigy and Sandoz merged and analysts say it’s a big success. The merger cost around 10,000 jobs but in the long-run more were created. The current CEO concedes that the merger also meant the loss of the Ciba corporate identity. Novartis’ profits shrank by a third in 2015, partly because…
This content was published on
The fear of missing out is a powerful motivator. Dealmaking in healthcare is often fuelled by a drive to outbid rivals for cutting-edge technology.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.